Cohera receives FDA IDE acceptance to initiate U.

Cohera receives FDA IDE acceptance to initiate U.S. Clinical study for TissuGlu Cohera Medical, Inc. The analysis will investigate the effectiveness of TissuGlu and its influence on wound drainage and connected complications in abdominoplasty surgeries. Related StoriesAlport syndrome: an interview with Dr Paul Grint, CMO, RegulusDiabetic retinopathy therapy improvements: an interview with Richard Kirk, CEO of PolyphotonixClinical trial suggests HIV patients should start therapy sooner rather than later’We are pleased to have FDA authorization to do this pivotal trial that validates the biocompatibility, pre-scientific testing profile and clinical trial style of TissuGlu,’ stated Chad Coberly, Vice President of Clinical, Regulatory and Legal Affairs of Cohera Medical.Infusion/Home Wellness Services income for the 3rd one fourth of 2011 was $109.6 million in comparison to $111.8 in the last year, a loss of $2.3 million, or 2.1 percent. Pharmacy Services income for the 3rd one fourth of 2011 was $344.5 million in comparison to $329.3 million for the last year period, a rise of $15.2 million, or 4.6 percent. Consolidated gross revenue for the 3rd one fourth of 2011 was $77.1 million, or 17.0 percent of revenue, in comparison to $75.4 million, or 17.1 percent of revenue, for the 3rd one fourth of 2010. Working income was $7.9 million, including $5.0 million of restructuring charges, acquisition, integration, severance and other employee costs in comparison to operating income of $12.2 million for the 3rd quarter of 2010, including $1.0 million of acquisition, integration, severance and other employee costs.

Other entries from category "doctor":

Random entries